Interferon Gamma-1B
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Interferon Gamma-1B
- Pharmacist Assessment Report
- Interferon gamma-1b: From an Unspecified Original Indication to Heart Disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Interferon gamma-1b: From an Unspecified Original Indication to Heart Disease
One-Sentence Summary
Interferon gamma-1b (Imukin) is a recombinant immunomodulatory cytokine marketed in Australia, but the registration data compiled for this report do not state its approved indication. The TxGNN model predicts it may be effective for heart disease (score 0.9999), but no clinical trials and no relevant publications support this prediction. The literature retrieved concerns other conditions, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the data compiled for this report |
| Predicted New Indication | Heart disease |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Interferon gamma-1b is a recombinant form of interferon gamma, an immunomodulatory cytokine. The data compiled for this report do not give its approved indication, so the link between its original use and the predicted indication cannot be assessed directly.
“Heart disease” is a broad, non-specific term. The TxGNN score is very high, but no clear mechanistic link is established. The three retrieved papers do not show a benefit in heart disease:
- A systematic review of interventions in Friedreich ataxia, a condition that has a cardiomyopathy component.
- A validation study of the six-minute-walk test in idiopathic pulmonary fibrosis.
- A case report of Mycobacterium chimaera prosthetic endocarditis, which is an infection-related cardiac condition.
On current evidence, this prediction is best treated as a model-generated signal that has not been supported by independent evidence.
The other nine predicted indications (for example Jeune syndrome with situs inversus, orofacial clefting syndrome, Pierre Robin syndrome, chromosomal deletion syndromes, Laubry-Pezzi syndrome and interventricular septum aneurysm) are developmental, structural or chromosomal conditions. They have no plausible interferon gamma-responsive mechanism and no retrieved evidence. Their scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, and all were rated L5 and Hold.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of the three papers below shows efficacy of interferon gamma-1b in heart disease.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37180421 | 2022 | Systematic review | Ther Adv Rare Dis | Reviews interventions in Friedreich ataxia, a rare neurodegenerative disease. It does not address interferon gamma-1b in heart disease. |
| 21131468 | 2011 | Validation study | Am J Respir Crit Care Med | Validates the six-minute-walk test in idiopathic pulmonary fibrosis. It is an outcome-measure study, not a drug trial. |
| 31020218 | 2018 | Case report | Eur Heart J Case Rep | Successful treatment of healthcare-associated M. chimaera prosthetic endocarditis. Interferon gamma may have been used as adjunctive immunotherapy, but this is not a heart disease indication. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 5769P | Imukin | Injection 2,000,000 I.U. in 0.5 mL | Not stated in the data compiled |
Safety Considerations
Drug Interactions: 57 interactions were identified. Examples of the major ones:
- Bupropion
- Deferiprone
- Iohexol
- Iopamidol
- Samarium (153Sm) lexidronam
Examples of moderate interactions include warfarin, dicoumarol, theophylline, aminophylline, oxtriphylline, roflumilast, naltrexone, chloramphenicol, avatrombopag, palifermin, strontium chloride Sr-89, lindane, and bowel preparations (picosulfuric acid, sodium sulfate, polyethylene glycol with electrolytes).
Warnings and contraindications data were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score. There are no clinical trials, and the retrieved literature does not address interferon gamma-1b in heart disease. The term “heart disease” is also too broad to guide development.
To proceed, the following is needed:
- The approved indication and Product Information from the TGA, including warnings and contraindications
- Mechanism of action data
- A specific cardiac condition in place of the broad “heart disease” label, with a plausible mechanistic rationale
- Targeted literature and trial searches for that condition
- A review of the interaction profile, particularly for patients on anticoagulants (e.g. warfarin) and other cardiac medicines
Note on other literature: Papers were retrieved for the fifth-ranked prediction (disorder of fucoglycosan synthesis), but they concern other diseases, including idiopathic pulmonary fibrosis, Friedreich ataxia, chronic granulomatous disease, cystic fibrosis lung disease and osteopetrosis. They do not support that prediction. Any value in them lies in separate evaluations of those indications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.